Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 35395680

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Neuro Oncol
Publication date
2022 Oct 3
First author
Desai AV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Desai AV
      type
      Author
    2. name
      Robinson GW
      type
      Author
    3. name
      Gauvain K
      type
      Author
    4. name
      Basu EM
      type
      Author
    5. name
      Macy ME
      type
      Author
    6. name
      Maese L
      type
      Author
    7. name
      Whipple NS
      type
      Author
    8. name
      Sabnis AJ
      type
      Author
    9. name
      Foster JH
      type
      Author
    10. name
      Shusterman S
      type
      Author
    11. name
      Yoon J
      type
      Author
    12. name
      Weiss BD
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Desai AV
      type
      Author
    2. name
      Robinson GW
      type
      Author
    3. name
      Gauvain K
      type
      Author
    4. name
      Basu EM
      type
      Author
    5. name
      Macy ME
      type
      Author
    6. name
      Maese L
      type
      Author
    7. name
      Whipple NS
      type
      Author
    8. name
      Sabnis AJ
      type
      Author
    9. name
      Foster JH
      type
      Author
    10. name
      Shusterman S
      type
      Author
    11. name
      Yoon J
      type
      Author
    12. name
      Weiss BD
      type
      Author
    bibliography ids
    1. nci-bib-c9a9ab6ee441a609d58f1d44
    book metadata
    content sha256
    be86d7cddd0ea3129c748767acaee12fc4ddde73872c5078cb188c100821de20
    document type
    citation
    dois
    1. 10.1093/neuonc/noac087
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:35395680
    immutable id
    pubmed:35395680@be86d7cddd0ea3129c748767acaee12fc4ddde73872c5078cb188c100821de20
    journal
    abbreviation
    Neuro Oncol
    issn electronic
    1523-5866
    issn print
    1522-8517
    issue
    10
    name
    Neuro-oncology
    nlm unique id
    100887420
    pages
    1776-1789
    volume
    24
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      35395680
      provenance
      batch id
      3f4d1914d2afe41e9e70
      provider
      NCBI PubMed ESummary
      record sha256
      d1b782a7e955df85a95aa0e3909e409eee513f4a455c88b8c7ea9642e32cb54a
      response sha256
      0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
      retrieved at
      2026-09-09T23:48:06.522634+00:00
      publication date
      display
      2022 Oct 3
      precision
      day
      year
      2022
      publication types
      1. Clinical Trial, Phase I
      2. Clinical Trial, Phase II
      3. Journal Article
      4. Research Support, Non-U.S. Gov't
      5. Research Support, N.I.H., Extramural
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/35395680/
      title
      Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

      Preserved source evidence · Independent clinical review pending · Not medical advice